Abstract
The key role of an inhibitory receptor, Programmed Death-1, has been evaluated in 273 patients with autoimmune myasthenia gravis. At the genetic level, SNP's genotyping showed no significant association to the disease. Gene expressions in patients were not different from that in controls. Interestingly, at the cell-surface protein level, there were significant elevated levels of PD-1 on T cells and its ligand PD-L1 on monocytes in the patients compared to controls. However, we could not demonstrate any secreted soluble forms of PD-1 among the patients and controls. Thus, our study shows PD-1 might have a natural regulatory property behind MG.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antigens, CD / analysis
-
Antigens, CD / genetics*
-
Antigens, CD / physiology*
-
Apoptosis Regulatory Proteins / analysis
-
Apoptosis Regulatory Proteins / genetics*
-
Apoptosis Regulatory Proteins / physiology*
-
Child
-
Female
-
Humans
-
Male
-
Membrane Proteins / analysis
-
Middle Aged
-
Myasthenia Gravis / etiology*
-
Myasthenia Gravis / genetics
-
Polymorphism, Single Nucleotide
-
Programmed Cell Death 1 Receptor
-
RNA, Messenger / analysis
Substances
-
Antigens, CD
-
Apoptosis Regulatory Proteins
-
Membrane Proteins
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
RNA, Messenger